Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
briciclib alaninate
- Development stage
- Unknown
- Lead developer
- Onconova Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Briciclib alaninate is a small molecule inhibitor of Cyclin D1 expression, originally developed by Onconova Therapeutics (as ON 013105) and licensed to Zai Lab for development in Greater China. It functions by inhibiting the translation of Cyclin D1 mRNA, likely through interaction with the eukaryotic translation initiation factor 4E (eIF4E) or the eIF4F complex, which is often overexpressed in various cancers. This downregulation leads to cell cycle arrest in the G1 phase and subsequent apoptosis. The drug has been primarily investigated for the treatment of advanced hepatocellular carcinoma (HCC) and other solid tumors. In a Phase 3 trial (CTR20180831) conducted by Zai Lab, it was evaluated as a second-line treatment for patients with advanced HCC.
- Other names
- briciclib
02
Targets
EIF4E (Eukaryotic translation initiation factor 4E)
Beyond the preview
Go deeper on briciclib alaninate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on briciclib alaninate.